^MAINZ, Germany, March 13, 2023 (GLOBE NEWSWIRE) – BioNTech SE
(https://biontech.de/) (Nasdaq: BNTX,?BioNTech” or?the company”) will be
Monday, March 27, 2023, the results of the financial year and the fourth
Release quarterly 2022. BioNTech will also be broadcast at 2:00 p.m. on the same day
MEZ to host a conference call and webcast with investment analysts to discuss the
Quarterly results and a corporate update for the fourth quarter and the
to present the entire financial year 2022 and invites investors as well as the
general public to participate.
To participate in the live conference call, please register via
this link
(https://register.event.com/register/BI80e9bb4e15bb407eae8899d0d0dd8f0b). After
You will be informed of the dial-in numbers including PIN when you register.
Please register at least one day in advance.
The presentation, including audio, will be streamed via this webcast link (https://edge.media-
server.com/mmc/p/z92gkz3s) to be available.
A live webcast and presentation will also be available at www.BioNTech.com
(https://www.biontech.com/de/de/home.html) under “Events & Presentations” in the
Investors section of the website made available. An audio recording of the
Presentation will be available on the website for 30 days after the end of the live webcast
published.
About BioNTech
Biopharmaceutical New Technologies is an immunotherapy company
next generation that will help develop therapies for cancer and others
serious illnesses is doing pioneering work. The company combines a
Variety of modern therapeutic platforms and bioinformatics tools to
Rapidly advance the development of novel biopharmaceuticals. The
diversified portfolio of oncology product candidates
individualized therapies and off-the-shelf drugs based on mRNA,
innovative chimeric antigen receptor (CAR) T cells, bispecific checkpoint
Immunomodulators, Targeted Cancer Antibodies and Small Molecules. Based
its extensive expertise in the development of mRNA vaccines and
of in-house manufacturing capabilities, BioNTech is developing alongside its
diverse oncology pipeline together with collaboration partners
various mRNA vaccine candidates for a range of infectious diseases.
BioNTech works side by side with world-renowned cooperation partners
from the pharmaceutical industry, including Genmab, Sanofi, Genentech (a
Roche Group companies), Regeneron, Genevant, Fosun Pharma and Pfizer.
For more information, visit: www.BioNTech.com
(https://www.biontech.com/de/de/home.html)
CONTACTS
investor inquiries
Michael Horowicz
+1 (617) 955 7420
[email protected] (mailto:[email protected])
Media Inquiries
Jasmina Alatovic
+49 (0)6131 9084 1513
[email protected] (mailto:[email protected])
°
Leverage must be between 2 and 20
No data